Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,764 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma Clear all
Terminated Phase 1Phase 2 Interventional Results available

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

NCT05397171
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 21, 2026, 6:51 PM EDT
Active, not recruiting No phase listed Observational

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

NCT05717998
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Recruiting No phase listed Observational

Pan-tumor MRD Study

NCT06605404
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
Interventions
blood and tissue samples, blood and tissue samples
Diagnostic Test · Other
Lead sponsor
Paradigm Health
Industry
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
San Diego, California • Maumee, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

NCT02357836
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Itraconazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Not applicable Interventional Results available

Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer

NCT02394548
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Interventions
Contralateral Esophageal Sparing Technique (CEST)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

NCT00553800
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 21, 2026, 6:51 PM EDT
Terminated Phase 1 Interventional

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

NCT00707252
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Polyphenon E, Tarceva
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

NCT00066885
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
calcitriol + docetaxel
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Berkeley, California • Vallejo, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Jul 21, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

NCT04367311
View directory record Official record
Conditions
Lung Cancer, NSCLC
Interventions
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Drug
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Not yet recruiting Phase 1 Interventional

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

NCT07382726
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Adagrasib, Iza-bren
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 21, 2026, 6:51 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
31
States / cities
Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Continued Access to RXDX-105

NCT03784378
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
Interventions
RXDX-105
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
BMS-986012 (anti-fucosyl-GM1), Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

NCT06333678
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

NCT03573947
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Paclitaxel
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 6:51 PM EDT
Recruiting No phase listed Observational

Biomarkers for Risk Stratification in Lung Cancer

NCT03774758
View directory record Official record
Conditions
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Interventions
Guardant Health ct-DNA LUNAR assay
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
590 participants
Timeline
2017 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
View directory record Official record
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Jul 21, 2026, 6:51 PM EDT
Terminated Phase 2 Interventional Results available

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674
View directory record Official record
Conditions
Lung Cancer
Interventions
PR104, F-18-fluoromisonidazole
Drug · Other
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Tucson, Arizona • Beverly Hills, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Jul 21, 2026, 6:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

NCT05388435
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SKL27969
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 21, 2026, 6:51 PM EDT